Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
5.75
+0.01 (0.17%)
At close: Mar 9, 2026, 4:00 PM EDT
5.71
-0.04 (-0.70%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Artiva Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | 0.25 | 33.49 | 4.93 | 2 | - | |
| Revenue Growth (YoY) | - | -99.25% | 579.21% | 146.30% | - | - | |
| Gross Profit | - | 0.25 | 33.49 | 4.93 | 2 | - | |
| Selling, General & Admin | 20.28 | 17.21 | 13.91 | 20.78 | 12.86 | 4.43 | |
| Research & Development | 65.86 | 50.33 | 50.25 | 43.98 | 42.41 | 13.85 | |
| Operating Expenses | 86.15 | 67.53 | 64.16 | 64.76 | 55.27 | 18.27 | |
| Operating Income | -86.15 | -67.28 | -30.67 | -59.83 | -53.27 | -18.27 | |
| Interest Expense | - | - | - | - | - | -0.2 | |
| Interest & Investment Income | 6.97 | 5.35 | 2.54 | 1.29 | - | 0 | |
| Other Non Operating Income (Expenses) | -2.36 | -5.78 | -0.97 | -0.2 | -18.55 | 0.48 | |
| EBT Excluding Unusual Items | -81.53 | -67.72 | -29.1 | -58.74 | -71.83 | -17.99 | |
| Gain (Loss) on Sale of Investments | 2.34 | 2.34 | 0.46 | - | - | - | |
| Pretax Income | -79.19 | -65.37 | -28.65 | -58.74 | -71.83 | -17.99 | |
| Income Tax Expense | - | - | 0.07 | 0.05 | - | - | |
| Net Income | -79.19 | -65.37 | -28.72 | -58.79 | -71.83 | -17.99 | |
| Net Income to Common | -79.19 | -65.37 | -28.72 | -58.79 | -71.83 | -17.99 | |
| Shares Outstanding (Basic) | 24 | 11 | 1 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 24 | 11 | 1 | 1 | 1 | 1 | |
| Shares Change (YoY) | 354.77% | 1302.54% | 4.70% | 11.80% | 8.60% | 3.59% | |
| EPS (Basic) | -3.25 | -5.81 | -35.78 | -76.67 | -104.73 | -28.49 | |
| EPS (Diluted) | -3.25 | -5.81 | -35.78 | -76.67 | -104.73 | -28.49 | |
| Free Cash Flow | -78.91 | -55.67 | -50.69 | -57.13 | -17.03 | -13.83 | |
| Free Cash Flow Per Share | -3.23 | -4.95 | -63.14 | -74.51 | -24.83 | -21.89 | |
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | - | |
| Operating Margin | - | -26805.58% | -91.58% | -1213.32% | -2660.94% | - | |
| Profit Margin | - | -26045.02% | -85.75% | -1192.21% | -3587.66% | - | |
| Free Cash Flow Margin | - | -22180.88% | -151.34% | -1158.55% | -850.55% | - | |
| EBITDA | -83.6 | -64.85 | -28.41 | -58.67 | -53.02 | -18.2 | |
| EBITDA Margin | - | - | -84.81% | - | - | - | |
| D&A For EBITDA | 2.55 | 2.43 | 2.27 | 1.16 | 0.25 | 0.07 | |
| EBIT | -86.15 | -67.28 | -30.67 | -59.83 | -53.27 | -18.27 | |
| EBIT Margin | - | - | -91.58% | - | - | - | |
| Revenue as Reported | 0.25 | 0.25 | 33.49 | 4.93 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.